Although QPS is complying with all government regulations for social distancing and allowing employees who can, to work from home, QPS Neuropharmacology is up and running. Please feel free to contact us any time to discuss your research needs.
QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Rare Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD) and other neurodegenerative and rare diseases.
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.
QPS Neuropharmacology provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.
As a leading CRO for CNS drug development, QPS Neuropharmacology is the premier provider for services with transgenic animals. We have more than 20 years of experience in generating, characterizing, and maintaining transgenic disease models and applying them for drug testing projects.
QPS Neuropharmacology's expertise lies within the field of neurodegenerative diseases. We provide a state of the art research environment (AAALAC certified) for testing and evaluating new potential treatment approaches.
QPS Neuropharmacology's well characterized and validated in vivo models are useful tools to push your CNS drug discovery research forward. We are happy to support your research activities with sample material from our biobank composed of various specimen derived from our in-house in vivo models.
The importance of microglia, the resident brain macrophages, in neurodegenerative diseases is well-known and these cells are therefore frequently used as a target for new pharmacological interventions.
At QPS Neuropharmacology, cell isolation of early postnatal microglia from mice is a well-established and standardized method for in vitro analysis of this specific cell type.
In addition, we recently set up a method to isolate microglial cells from adult mice by Magnetic Cell Sorting (MACS). Generation of a pure microglial fraction from adult brains of transgenic or even compound-treated mice opens a variety of new possibilities to assess the efficacy of treatments. The cell type specific analysis of gene expression, biomarkers or even additional cultivation and stimulation of these cells can answer unresolved questions.
Purity of the microglial fraction in comparison to the fraction containing all remaining cells (flow through, FT) was assessed by mRNA analysis of the microglial marker Itgam (CD11b) as well as the astrocytic marker GFAP (Fig 1). The results show a strong enrichment of Itgam positive cells in the microglial fraction compared to the FT (Fig 1A), in combination with an absence or extremely low contamination of GFAP expression in the microglial fraction (Fig 1B).
Furthermore, as an example of cell type specific mRNA expression, analysis of IL-6 and MYD88 via RT-PCR was performed in microglia isolated from 5xFAD mice compared to non-transgenic littermates (Fig.2). Interestingly, a high increase in IL-6 expression is accompanied by a reduced MYD88 expression level in microglia of aged 5xFAD mice.
Figure 1: RT-PCR amplification graphs of (A) Itgam and (B) GFAP SYBR green signal in 3 microglia and flow through fractions prepared from 3 separate 9.5 months old mouse brains. The graph shows relative fluorescence units (RFU) of the SYBR green signal per cycle.
Figure 2: IL-6 and MYD88 mRNA expression level in microglial fraction of non-transgenic (nTG) and 5xFAD mouse brains at 9.5 months of age. Data are given as x-fold change compared to nTG mice and shown as bar graphs +SD (n=4-5 per group). Statistical analysis: unpaired t-test. *p<0.05; **p<0.01.